Evidence map›Paper›PMID 39523927›Full record

ArticleThe Prostate2025

pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy.

Piotr Bialas, Tamae Kobayashi, Rebecka Hellsten, Agnieszka Krzyzanowska, Margareta Persson, Felicia Marginean, Dominique Trudel, Isla P Garraway, Bruce J Trock, Pekka Taimen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Piotr BialasDepartment of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden.ORCID 0000-0001-9133-4177
Tamae KobayashiDepartment of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden.
Rebecka HellstenDepartment of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden.ORCID 0000-0002-3735-5636
Agnieszka KrzyzanowskaDepartment of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden.ORCID 0000-0002-1288-7054
Margareta PerssonDepartment of Laboratory Medicine, Translational Cancer Research, Lund University, Lund, Sweden.
Felicia MargineanDepartment of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden.
Dominique TrudelCentre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montréal, Montreal, Quebec, Canada.
Isla P GarrawayDepartment of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Bruce J TrockDepartment of Urology and Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Pekka TaimenInstitute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland.
Fred SaadDepartment of Surgery, Université de Montréal, Montreal, Quebec, Canada.
Tuomas MirttiHUS Diagnostic Center, Department of Pathology, HUS Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0003-0455-9891
Beatrice KnudsenDigital and Computational Pathology, University of Utah, Salt Lake City, Utah, USA.
Angelo M De MarzoDepartment of Urology and Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Anders BjartellDepartment of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden.ORCID 0000-0002-5761-3786

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI NELSON, WILLIAM GEORGE · 1992 to 2020
$43.9M
Mechanisms of Prostate Cancer MetastasisR01CA271750 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FREEMAN, MICHAEL R., GARRAWAY, ISLA PEARL · 2021 to 2025
$2.2M
NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA058236NCI NIH HHS R01 CA271750This work was supported by Swedish Scientific Council, ALF Lund University, Kungliga Fysiografiska Sallskapet i Lund, Movember Foundation, NIH/NCI SPORE, Fonds de Recherche du Québec-Santé and Swedish Cancer Foundation.
6 · The paper itself

Abstract

backgroundThe transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) plays a role in carcinogenesis and is involved in processes, such as proliferation, differentiation, drug resistance and immunosuppression. STAT3 can be activated by phosphorylation of tyrosine at position 705 (pSTAT3

methodsThe study cohort came from a PCa tissue microarray resource containing prostate specimens from patients before and post-initiation of ADT. Tissue samples from 111 patients were immunostained for pSTAT3

resultsPost-ADT PCa samples demonstrated increased nuclear and cytoplasmic levels of pSTAT3

conclusionsThis study presents novel insights into the impact of ADT on the expression levels of pSTAT3

Indexed as

Androgen AntagonistsProstatic NeoplasmsSTAT3 Transcription FactorAgedAged, 80 and overCohort StudiesHumansMaleMiddle AgedPhosphorylationTissue Array AnalysisAndrogen AntagonistsSTAT3 protein, humanSTAT3 Transcription Factorandrogen deprivation therapyandrogensbiomarkersprostate cancerSTAT3

Identifiers

PMID39523927
PMCPMC11720397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.